Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc

Bullboard Posts

Comment by pabalooon Nov 05, 2020 2:16pm

103 Views

Post# 31843352

RE:Sun Pharma Q2 excerpt on Absorica LD

Just a heads up Nozz there is nothing out of Teva or Activis on the generic front of a Absorica generic. Not sure why but they I think they need to apply for FDA status to launch which as far as I can tell has still not happened. Maybe Covid or possible flat numbers from Absorica sales has affected the margin to launch against it. On the Sun call it was alluded to "if" a generic is launched. We will know shortly either way.

Bullboard Posts

E3 inches closer to Alberta's first lithium production plant